Αρχική World News Subcutaneous Daratumumab Monotherapy for Patients with High-Risk Smoldering Multiple Myeloma World News Subcutaneous Daratumumab Monotherapy for Patients with High-Risk Smoldering Multiple Myeloma Από Ogkologos - 18 Δεκεμβρίου, 2024 1108 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AQUILA study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Immunotherapy Drugs Expand Treatment Options for Advanced Lung Cancer 27 Απριλίου, 2018 Research with integrity – why building networks is vital for integrity 22 Μαρτίου, 2023 ΝΕΥΡΟΕΝΔΟΚΡΙΝΕΙΣ ΟΓΚΟΙ (ΝΕΤS) 7 Φεβρουαρίου, 2019 A Message from the ESMO President 17 Μαρτίου, 2020 Φόρτωση περισσοτέρων HOT NEWS Resilience Isn’t About Bouncing Back FDA Approves Belumosudil to Treat Chronic Graft-Versus-Host Disease Cancer Immunotherapy Drug Simultaneously Targets Two Proteins that Block Immune Response Reflecting On My Time As the Cancer.Net Editor in Chief